 GBS Inc NASDAQ:GBS will prepare for clinical trials of its rapid SARS-CoV-2 COVID-19 Antibody test following the recent successful completion of a clinical validation study. As previously referenced, a clinical validation study was conducted at the Wyss Institute for Biologically Inspired Engineering at Harvard University. 